Purpose: To report an incident of a breakthrough deep vein thrombosis (DVT) and potential example of a drug-drug interaction in a patient treated with edoxaban and rifabutin who was being treated for respiratory tuberculosis. Case: A 76-year-old male presented with anemia requiring transfusion and subsequent shortness of breath that was later diagnosed to be respiratory tuberculosis. He experienced a prolonged hospital stay due to persistently positive Mycobacterium tuberculosis respiratory samples and a complicated social situation that required continuous hospitalization for approximately five months. During his treatment the patient was transitioned from apixaban to edoxaban due to a drug-drug interaction with rifabutin. He subsequently had a DVT while on edoxaban after two months of therapy that would require him to transition to warfarin. Conclusion: This case represents an example of a potentially significant drug-drug interaction between edoxaban and rifabutin. Other direct oral anticoagulants (DOACs) exhibit a potential drug-drug interaction that limit their effectiveness when used with rifamycins. This report describes the first known case of a patient experiencing a DVT after prolonged edoxaban use in combination with rifabutin. Treatment with DOACs for patients taking concomitant cytochrome P450 (CYP) inducers such as rifabutin may be more complicated than previously believed.
JanuaryCTWannLSCalkinsH, et al.2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665.
2.
OrtelTLNeumannIAgenoW, et al.American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830.
3.
AgnelliGBullerHRCohenA, et al.Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.
4.
GrangerCBAlexanderJHMcMurrayJJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039.
5.
GiuglianoRPRuffCTBraunwaldE, et al.Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907.
6.
SchulmanSKearonCKakkarAK, et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598.
7.
PatelMRMahaffeyKWGargJ, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638.
8.
EINSTEIN InvestigatorsBauersachsRBerkowitzSD, et al.Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903.
9.
Hokusai-VTE InvestigatorsBüllerHRDécoususH, et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638.
10.
ConnollySJEzekowitzMDYusufS, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561.
11.
ParasrampuriaDATruittKE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that Inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641-655. doi:10.1007/s40262-015-0342-7.
12.
BurnettAEMahanCEVazquezSROertelLBGarciaDAAnsellJ. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206-232. doi:10.1007/s11239-015-1310-7.
13.
MendellJChenSHeLDesaiMParasramupriaDA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447-453. doi:10.1007/s40261-015-0298-2.
14.
CorsiniAFerriNProiettiMBorianiG. Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs. 2020;80(11):1065-1083. doi:10.1007/s40265-020-01328-6.
15.
FerriNColomboETenconiMBaldessinLCorsiniA. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022;14(6):1120. doi:10.3390/pharmaceutics14061120.
16.
Savaysa (Edoxaban) [package Insert]. Tokyo, Japan: Daiichi Sankyo, Inc.; 2021.
17.
HornJRHanstenPDChanLN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-680. doi:10.1345/aph.1H423.
18.
HochheiserHJingXGarciaEA, et al.A minimal information model for potential drug-drug interactions. Front Pharmacol. 2020;11:608068. doi:10.3389/fphar.2020.608068.
19.
SennesaelALLarockASHainautP, et al.The impact of strong inducers on direct oral anticoagulant levels. Am J Med. 2021;134(10):1295-1299. doi:10.1016/j.amjmed.2021.06.003.
20.
HerinkMCZhuoYFWilliamsCDDeLougheryTG. Clinical management of Pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs. 2019;79(15):1625-1634. doi:10.1007/s40265-019-01183-0.
21.
FinchCKChrismanCRBaciewiczAMSelfTH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162(9):985-992. doi:10.1001/archinte.162.9.985.
22.
BaciewiczAMChrismanCRFinchCKSelfTH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1-12. doi:10.1185/03007995.2012.747952.
23.
MacDougallCCanonicaTKehCP PhanBALouieJ. Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. Pharmacotherapy. 2022;42(4):343-361. doi:10.1002/phar.2672.
24.
LutzJDKirbyBJWangL, et al.Cytochrome P450 3A induction Predicts P-glycoprotein induction; Part 2: Prediction of decreased Substrate Exposure after rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191-1198. doi:10.1002/cpt.1072.
25.
LutzJDKirbyBJWangL, et al.Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: Establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104(6):1182-1190. doi:10.1002/cpt.1073.
26.
TuloupVFranceMGarreauR, et al.Model-based comparative analysis of rifampicin and rifabutin drug-drug interaction profile. Antimicrob Agents Chemother. 2021;65(9):e0104321. doi:10.1128/AAC.01043-21.
27.
ColonnaPvon HeymannCSantamariaA, et al.Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: the prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol. 2020;43(7):769-780. doi:10.1002/clc.23379.
28.
SherwoodMWDouketisJDPatelMR, et al.Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129(18):1850-1859. doi:10.1161/CIRCULATIONAHA.113.005754.
29.
PerlmanAHochberg-KleinSChoshen CohenL, et al.Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis. 2019;47(4):590-595. doi:10.1007/s11239-018-01804-7.
30.
HwangKWChoiJHLeeSY, et al.Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):182. doi:10.1186/s12872-023-03212-z.
